AzTrials
AzTrials

PainNCT06869928

Implementation of the Pain and Irritability of Unknown Origin (PIUO) Pathway in Community Pediatric Practices

A study testing PIUO Pathway in people with Pain and Irritability, run by University of British Columbia at 1 site in Canada.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The Pain and Irritability of Unknown Origin (PIUO) Pathway is a clinical pathway that was developed to evaluate and manage unexplained pain and irritability for children with severe neurological impairments (SNI) who cannot verbally communicate 'where it hurts'. Read more about this study

Who is it for?
Ages 6 months to 18 years
Conditions the study is for
Pain, Irritability, Neuropathic Pain
What is being tested?
PIUO Pathway
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteCanada
Study dates
28 Jun 2024to May 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 months to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Pain Pathway Intervention Inclusion Criteria:

  • Children aged 6 months to 18 years with SNI (from any cause) with unexplained pain and irritability and whose cognitive or communication impairments prevent determination of pain location, cause, and type will be eligible to participate.
  • Eligible children will have cognitive impairment or be non-verbal. Parents should have sufficient English skills, or have access to assistance, to participate in the clinic visits and complete survey tools.

Pain Pathway Intervention Exclusion Criteria:

  • Children not within the specified age range
  • Children with communication capabilities and cognitive development to localize their pain
  • Children that have an explained and treatable cause of pain and irritability. Parents that do not have sufficient English skills, or have access to assistance, to participate in the clinic visits and complete survey tools.

Implementation Participant Inclusion Criteria:

  • General pediatricians
  • Practicing in a community clinic in British Columbia

Implementation Participant Exclusion Criteria:

  • Healthcare professionals who are not general pediatricians (e.g., pediatrician specialists, nurse practitioners, nurses, other allied health professionals)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Anne-Mette Hermansen, MA contact

604-875-2000 ext. 6909

ahermansen@bcchr.ca

Canada1 site, 1 recruiting
  • BC Children's Hospital

    Vancouver, British Columbia, V6H 3V4

    Anne-Mette Hermansen

    Recruiting

Other trials in Canada

About this study

The Pain and Irritability of Unknown Origin (PIUO) Pathway is a clinical pathway that was developed to evaluate and manage unexplained pain and irritability for children with severe neurological impairments (SNI) who cannot verbally communicate 'where it hurts'. The investigators studied the usefulness of the Pathway with families and expert clinicians in 4 centres across Canada. The aim of this Phase 2 study is to determine whether this tool can transfer from hospital research centres into the community. The Pathway will be used by community pediatricians across British Columbia (BC) when they see patients with PIUO. The investigators want to know how well these pediatricians can follow the Pathway. The goal is to create a systematic, cohesive approach to enhance the clinical care for all children with complex medical needs experiencing PIUO.

Read the detailed description

BACKGROUND: Many children with brain-based developmental disorders and their families, specifically those with SNI, experience on-going and difficult-to-treat PIUO. However, currently, no consensus exists among healthcare providers about how to best approach PIUO, which likely exacerbates the challenges in faced by parents in taking care of their children with SNI experiencing PIUO. The PIUO Pathway was developed to streamline pain management and care for these children, who are among the most vulnerable seen in any hospital or clinic. To-date, the PIUO Pathway has only been used by expert clinicians in complex care, palliative medicine, and pain medicine, and in tertiary pediatric care settings. Community pediatricians are not yet trained to use this tool, which limits access of such care to the tertiary care level and/or through access to specialist supports. Training front-line clinicians, specifically community pediatricians, to use the PIUO Pathway holds the potential to delivering sustained, effective, and quality community care that can better serve and reach this vulnerable population of Canadian children and families.

AIMS: To advance the assessment and treatment of PIUO in children with SNI and their families, the primary aims and respective research questions of this hybrid implementation-effectiveness study are:

Primary Implementation Aim 1: To determine the feasibility and effectiveness of, and factors that influence implementing the Pain Pathway. Specifically, do the implementation strategies show promise in facilitating the implementation of the Pain Pathway in community practice?

Primary Intervention Aim 2: To assess the effectiveness of the Pain Pathway intervention on relevant outcomes of children with SNI and their families. Specifically, does the Pain Pathway work to help manage PIUO for children with SNI presenting and their families when seen in a community practice?

METHODS

Study Design

The investigators will conduct a hybrid implementation-effectiveness feasibility study using a pre-post, quasi-experimental design. The study will run from 2023 to 2025. Since the Pain Pathway's effectiveness has not been tested previously in a community pediatric practice setting, the investigators selected a Type 2 hybrid effectiveness-implementation design to determine if the Pain Pathway can be feasibly implemented in a real-world (community-based) setting, while further testing the effectiveness of the intervention under a different condition. A hybrid design can offer a more rapid and efficient means to gather information on the effectiveness of the implementation and intervention, as well as to translate knowledge to practice.

Implementation will be guided by the National Implementation Research Network (NIRN)'s Active Implementation Frameworks. The Active Implementation Frameworks (AIF) is an evidence-based set of process frameworks used to facilitate the successful implementation of innovation into practice, including the delivery of evidence-based health services. The investigators will also refer to the NIRN Implementation Stages Planning Tool to support implementation development. Implementation will be conducted in an integrated, non-linear process across the four stages of the AIF: Stage 1 - Exploration; Stage 2 - Installation; Stage 3 - Initial Implementation; and Stage 4 - Full Implementation. Conducting implementation activities in a stepwise manner will allow the investigators to study the implementation in its entirety, including planning, preparing, training, evaluation, and sustainability.

The investigators will use the Theoretical Domains Framework (TDF) to identify barriers and facilitators to implementation. The investigators will also refer to the Behavioural Change Wheel (BCW) to identify priority mechanisms of action that underlie the selection of implementation strategies, which will target the priority barriers and facilitators that the investigators identify.

The Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework will be used to evaluation implementation processes and outcomes. RE-AIM is an integrated framework developed to support the adoption and sustainable implementation of evidence-based interventions in a wide range of health, public health, and community settings.

Intervention Components

The intervention being implemented consists of two components:

  1. Pain Pathway: The Pain Pathway targets PIUO in an intentional, focused, timely, sequential order of standardized steps to support best outcomes for children with SNI and families. It is comprised of 2 steps. Step 1 asks the pediatrician to conduct a thorough history that includes a pain history to identify known and unknown sources of past and current pain, and a physical examination. Step 2 involves carrying out a series of screening tests to explore any potential underlying disease or injury, if not apparent based on Step 1. These tests may include urinalysis, ultrasound, gastric pH, and bloodwork. Each child proceeds through the Pain Pathway as long as their pain persists, but may not go through all steps if their pain source is identified or pain resolves at any stage. The steps of the Pain Pathway may be refined by the study team based on the results of Phase 1 study analysis (NCT03464773), which is underway.
  2. Nursing Support: An observation made in the pilot and again in the Phase 1 RCT was that the nurse-family interaction that was provided was perceived to be therapeutic both in cases where a treatable pain source was identified, and in cases when they were not. Therefore, elucidating the impact of nursing support and the nurse-family interaction on patient and family outcomes will be an important intervention evaluation component of this study. A central study nurse will be available to work closely with and consult with community pediatricians at each clinic. Nursing support will be defined as any contact or interaction with families in the context of delivering the Pain Pathway, including communication, consultation, psychosocial support, and service and resource coordination, and quality of and satisfaction with nurse-family interaction as reported by parents of children with SNI partaking in the Pain Pathway.

Hypothesized Mechanisms of Change and Implementation Strategies

The implementation strategies will be developed based on the results of the TDF-guided barrier and facilitator assessment of BC community paediatricians. The investigators will select empirically supported implementation strategies to fulfill each mechanism of action identified as relevant through the BCW, while targeting priority barriers and facilitators. The investigators hypothesize that the intervention functions of education, training, and modeling will likely form the foundation of the implementation strategies because the investigators anticipate that barriers to implementation will include a lack of knowledge of the Pain Pathway (knowledge - education) and how to apply it to practice (training), as well as the limited number of pediatricians with expertise in complex care, pediatric pain, and palliative medicine (lack of confidence in managing complex pain - modelling).

Being tested
PIUO Pathway
Keywords
Pain, Irritability, Pediatrics, Community, Neuropathic Pain, Severe Neurological Disabilities, Implementation Science, Patient Engagement
Medical subject headings
Pain, Neuralgia, Patient Participation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PIUO PathwayOther

    see arm description.

Study groups in NCT06869928
Study groupRoleWhat they receive
PIUO PathwayOtherThe PIUO Pathway targets PIUO in an intentional, focused, timely, sequential order of standardized steps to support best outcomes for children with SNI and families. The PIUO Pathway is comprised of 2 steps. Step 1 is for the pediatrician to conduct a thorough history that includes a pain history to identify known and unknown sources of past and current pain, and a physical examination. Step 2 is to carry out a series of screening tests to further explore any potential underlying disease or injury if not apparent based on the Step 1 history and physical examination. The standard screening tests may include urinalysis, ultrasound, gastric pH, and bloodwork. Each child proceeds through the Pain Pathway as long as their pain persists but may not go through all steps if their pain source is identified or pain resolves at any stage. The Steps of the Pain Pathway may be refined by the team based on the results of Phase 1 study analysis, which is underway.
Receives: Other: PIUO Pathway

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Implementation Adoption

    Adoption of the Pain Pathway will be measured by completion rates, self-reported by community pediatricians.

    Measured: End of the Pain Pathway, an average of 1 year to 18 months

  2. Implementation Reach

    Reach of the Pain Pathway will be measured by recruitment and retention rates of community pediatricians, self-reported by community pediatricians.

    Measured: Baseline and end of the Pain Pathway, an average of 1 year to 18 months

  3. Implementation Acceptability

    Acceptability of the Pain Pathway will be measured by level of satisfaction (e.g., 1 = very unsatisfied; 7 = very satisfied) based on a Likert scale and self-reported by community pediatricians. Scores will be averaged and higher scores reflect higher levels of satisfaction/acceptability.

    Measured: End of the Pain Pathway, an average of 1 year to 18 months

  4. PIUO Pain Pathway Effectiveness

    Effectiveness of the PIUO Pain Pathway will be measured by proportion of children with SNI and families who received appropriate steps of investigation and treatment options based on following the steps of the PIUO Pain Pathway.

    Measured: End of the Pain Pathway, an average of 1 year to 18 months

Secondary outcomes (3)
  1. Pain and Irritability (PIUO)

    Number of participants whose pain and irritability (PIUO) scores are lower over time, measured by the parent-reported Pain Survey.

    Measured: Baseline and end of the Pain Pathway, an average of 1 year to 18 months

  2. Family Well-being

    Family well-being, measured by standardized measures of well-being (e.g., PROMIS-57; 1 = unable to do; 5 = without any difficulty) based on parent/caregiver-report of their child and family unit (scoring min. = 8 and max. = 40). Scores are converted to T-scores (mean T-score = 50; standard deviation = 10).

    Measured: Baseline and end of the Pain Pathway, an average of 1 year to 18 months

  3. Factors Influencing Implementation

    Factors influencing implementation, including barriers and facilitators and health equity-related, will be measured by identification of these factors through survey and interviews with community pediatricians.

    Measured: Baseline and end of the Pain Pathway, an average of 1 year to 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Mar 2025
  2. Study start28 Jun 2024
  3. Primary completionMar 2026 (estimated)
  4. Study completionMay 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Model description
The investigators will conduct a hybrid implementation-effectiveness study using a pre-post, quasi-experimental design. This study adheres to a patient-oriented research framework, integrates principles of equity, diversity, inclusion, and decolonization in the research process, and includes an integrated knowledge mobilization plan.
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06869928
Sponsor's protocol ID
H24-00078
Status last verified
Mar 2025
First submitted
28 Jun 2024
Last updated
11 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing PIUO Pathway in people with Pain and Irritability, run by University of British Columbia at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 11 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sharon Hou, PhD (604-875-2345 ext. 5300, sharon.hou@bcchr.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Implementation Adoption (time frame: End of the Pain Pathway, an average of 1 year to 18 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in